Primary Tumor Location Is a Predictor of Poor Prognosis in Patients with Locally Advanced Esophagogastric Cancer Treated with Perioperative Chemotherapy

Felismino, Tiago; Oliveira, Audrey; Alves, Ana Caroline; Costa, Wilson Luiz da; Coimbra, Felipe J. F.; Begnami, Maria D.; Riechelmann, Rachel P.; Jesus, Victor Hugo Fonseca de; Mello, Celso Abdon Lopes de

doi:10.1007/s12029-019-00258-1

Cited by 7 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients with gastric cancer have reached the middle and late stages at the time of diagnosis. Even if perioperative chemotherapy or adjuvant chemotherapy is used, the survival rate of these patients is still low [ 3 , 4 ]. Therefore, the search for new therapeutic approaches, such as molecular targeted therapy, has become a hot topic in gastric cancer research.…”

Section: Introductionmentioning

confidence: 99%

Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer

Yun

Wang

Jiang

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

Objective. To explore the relationship between the HER2 gene and PD-1/PD-L1 in gastric cancer and its significance. Methods. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) were used to detect HER2 protein expression, HER2 gene amplification, and PD-1/PD-L1 expression in 78 cases of gastric cancer. Results. The expression rate of HER2 protein was 43.6% (34/78), of which 19.4% (14/78) were HER2 3+, 14.1% (11/78) were HER2 2+, and 11.5% (9/78) were HER2 1+. The results showed that 19.2% (15/78) of samples had HER2 gene amplification, 3.8% (3/78) of samples had a HER2/CEP17 ratio <2.0, and 19.2% (15/78) of samples had HER2 gene amplificationf and HER2 copy/cell ≥6.0, as detected by FISH. The positive rate of PD-L1 was 38.5% (30/78) in gastric cancer cells and 50.0% (39/78) in interstitial lymphocytes. The expression of the HER2 gene, PD-L1, and PD-1 in gastric cancer was correlated with the stage and lymph node metastasis of gastric cancer ( P < 0.05 ). Conclusions. The combined detection of the HER2 gene and PD-1/PD-L1 in gastric cancer provides an important reference index for the prognosis of gastric cancer and the benefit of targeted antitumor drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer

Yun

Wang

Jiang

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated this strategy to yield increased rates of complete resection, downstaging, overall survival, and progression-free survival 3,8 . It has also been noted that some tumors exhibit better responsiveness than others 7,8 . Therefore, diagnostic methods that can predict a complete pathological response (pCR) have important clinical implications 7,22 .…”

Section: Introductionmentioning

confidence: 99%

“…It has also been noted that some tumors exhibit better responsiveness than others 7,8 . Therefore, diagnostic methods that can predict a complete pathological response (pCR) have important clinical implications 7,22 . Several combined chemotherapy regimens have shown good efficacy for GC and non-resectable GEJ allowing a potential curative gastrectomy 22 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Endoscopic Characteristics of Patients With Complete Pathological Response After Neoadjuvant Chemotherapy for Gastric and Esophagogastric Junction Adenocarcinomas

Castro

Pelosof

Andrade-Cabral

et al. 2021

ABCD, arq. bras. cir. dig.

View full text Add to dashboard Cite

Background: Gastric and esophagogastric junction adenocarcinoma are responsible for approximately 13.5% of cancer-related deaths. Given the fact that these tumors are not typically detected until they are already in the advanced stages, neoadjuvancy plays a fundamental role in improving long-term survival. Identification of those with complete pathological response (pCR) after neoadjuvant chemotherapy (NAC) is a major challenge, with effects on organ preservation, extent of resection, and additional surgery. There is little or no information in the literature about which endoscopic signs should be evaluated after NAC, or even when such re-evaluation should occur. Aim: To describe the endoscopic aspects of patients with gastric and esophagogastric junction adenocarcinomas who underwent NAC and achieved pCR, and to determine the accuracy of esophagogastroduodenoscopy (EGD) in predicting the pCR. Methods: A survey was conducted of the medical records of patients with these tumors who were submitted to gastrectomy after NAC, with anatomopathological result of pCR. Results: Twenty-nine patients were identified who achieved pCR after NAC within the study period. Endoscopic responses were used to classify patients into two groups: G1-endoscopic findings consistent with pCR and G2-endoscopic findings not consistent with pCR. Endoscopic evaluation in G1 was present in an equal percentage (47.4%; p=0.28) in Borrmann classification II and III. In this group, the predominance was in the gastric body (57.9%; p=0.14), intestinal subtype with 42.1% (p=0.75), undifferentiated degree, 62.5% (p=0.78), Herb+ in 73.3% (p=0.68). The most significant finding, however, was that the time interval between NAC and EGD was longer for G1 than G2 (24.4 vs. 10.2 days, p=0.008). Conclusion: EGD after NAC seems to be a useful tool for predicting pCR, and it may be possible to use it to create a reliable response classification. In addition, the time interval between NAC and EGD appears to significantly influence the predictive power of endoscopy for pCR.

show abstract

“…Xu et al (11) reported that log odds of positive lymph nodes can predict the prognosis of patients with Siewert type II AEG. Felismino et al (12) believes that the prognosis of locally advanced esophagogastric cancer can be determined by pathological staging and primary site. Kudou et al (13) believes that postoperative sarcopenia can be used as a prognostic indicator for AEG, but these indicators are postoperative.…”

Section: Introductionmentioning

confidence: 99%

Preoperative Neutrophil Lymphocyte Ratio Can Be Used as a Predictor of Prognosis in Patients With Adenocarcinoma of the Esophagogastric Junction: A Systematic Review and Meta Analysis

et al. 2020

View full text Add to dashboard Cite

Objective: Neutrophil lymphocyte ratio (NLR), Lymphocyte mononuclear cell ratio (LMR), and Platelet lymphocyte ratio (PLR) can be used as various prognostic factors for malignant tumors, but the value of prognosis for patients with adenocarcinoma of the esophagogastric junction (AEG) has not been determined. This study used meta-analysis to assess the value of these indicators in the evaluation of AEG prognosis. Methods: Relevant literatures on the prognostic relationship between NLR, LMR, PLR, and AEG was retrieved from PubMed, Web of Science, Embase, Cochrane Library, Cochrane Central Register of Controlled Trials, Wanfang data, and Chinese National Knowledge Infrastructure. The search time from database establishment to June 30, 2019. The language is limited to English and Chinese. Data was analyzed using Stata 15.0 software. Result: Six retrospective studies were included, five of them involved NLR and six of them involved PLR. No LMR literature that adequately satisfied the conditions was retrieved. Increased NLR was significantly associated with a significant reduction in overall survival (OS), cancer-specific survival (CSS), or disease specific survival (DSS) in patients with AEG [hazard ratio (HR) = 1.545, 95% CI: 1.096-2.179, P < 0.05]. Subgroup analysis showed that NLR had significant value in the prognosis of both Chinese and Non-Chinese patients (P = 0.009 vs. P = 0.000). NLR had significant prognostic value for ≥3 and <3 groups (P = 0.022 vs. P = 0.000). NLR has a significant prognostic value for samples ≥500 and <500 (P = 0.000 vs. P = 0.022). NLR and OS/CSS/DSS single factor meta-regression showed that regional NLR cutoff values and sample size may be the source of heterogeneity in AEG patients (all P < 0.05). There was no significant association between elevated PLR and OS in patients with AEG (HR = 1.117, 95% CI: 0.960-1.300, P > 0.05). PLR had no significant prognostic value for both Chinese and Liu et al. NLR Can Be Used as a Predictor of AEG UK patients (P = 0.282 vs. P = 0.429). PLR had no significant prognostic value for ≥150 group and <150 group (P = 0.141 and P = 0.724). No significant prognostic value was found in either the 300 group and <300 group (P = 0.282 vs. P = 0.429). Conclusion: Preoperative NLR rise was an adverse prognostic indicator of AEG. High-risk patients should be treated promptly. The results showed that PLR was not recommended as a prognostic indicator of AEG.

show abstract

Primary Tumor Location Is a Predictor of Poor Prognosis in Patients with Locally Advanced Esophagogastric Cancer Treated with Perioperative Chemotherapy

Cited by 7 publications

References 31 publications

Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer

Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer

Endoscopic Characteristics of Patients With Complete Pathological Response After Neoadjuvant Chemotherapy for Gastric and Esophagogastric Junction Adenocarcinomas

Preoperative Neutrophil Lymphocyte Ratio Can Be Used as a Predictor of Prognosis in Patients With Adenocarcinoma of the Esophagogastric Junction: A Systematic Review and Meta Analysis

Contact Info

Product

Resources

About